Summary
-
Xeris Biopharmaceuticals has shown strong technical buy signals, with a 30.03% gain since the Trend Seeker buy signal on 1/28.
The Barchart Brief: Your FREE insider update on the biggest news stories and investing trends, delivered midday The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies.
Barchart indicators show 100% technical buy signals, a 95.32% gain in the last year, and a Trend Seeker buy signal.
Analysts are bullish with 4 strong buys, 1 buy, and 1 hold, despite MorningStar's view of the stock being 12% overvalued.